Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:CELU NASDAQ:LONA NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$3.90+7.1%$4.69$3.35▼$17.94$79.41M4.47174,432 shs130,071 shsCELUCelularity$0.71-1.9%$1.02$0.67▼$4.35$21.04M0.48136,004 shs35,479 shsLONAAthira Pharma$8.35-1.6%$9.52$2.85▼$14.21$79.75M1.9732,450 shs15,563 shsRNTXRein Therapeutics$0.96+3.5%$1.27$0.89▼$2.18$79.18M1.35471,305 shs721,485 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+7.14%+5.98%-40.82%-23.38%-65.46%CELUCelularity-1.91%-18.27%-9.37%-41.57%-60.39%LONAAthira Pharma-1.65%+1.58%-19.09%+9.01%+834,999,900.00%RNTXRein Therapeutics+3.49%+1.57%-17.42%-26.32%-50.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$3.90+7.1%$4.69$3.35▼$17.94$79.41M4.47174,432 shs130,071 shsCELUCelularity$0.71-1.9%$1.02$0.67▼$4.35$21.04M0.48136,004 shs35,479 shsLONAAthira Pharma$8.35-1.6%$9.52$2.85▼$14.21$79.75M1.9732,450 shs15,563 shsRNTXRein Therapeutics$0.96+3.5%$1.27$0.89▼$2.18$79.18M1.35471,305 shs721,485 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+7.14%+5.98%-40.82%-23.38%-65.46%CELUCelularity-1.91%-18.27%-9.37%-41.57%-60.39%LONAAthira Pharma-1.65%+1.58%-19.09%+9.01%+834,999,900.00%RNTXRein Therapeutics+3.49%+1.57%-17.42%-26.32%-50.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70405.13% UpsideCELUCelularity 2.00Hold$6.00741.63% UpsideLONAAthira Pharma 2.40Hold$15.0079.64% UpsideRNTXRein Therapeutics 2.00Hold$7.00630.77% UpsideCurrent Analyst Ratings BreakdownLatest CELU, LONA, RNTX, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026RNTXRein Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/ACELUCelularity$26.55M0.78N/AN/A($1.32) per share-0.54LONAAthira PharmaN/AN/AN/AN/A$2.98 per shareN/ARNTXRein TherapeuticsN/AN/A$0.06 per share16.19($1.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/ACELUCelularity-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)LONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/ARNTXRein Therapeutics-$49.87M-$1.90N/AN/AN/AN/A-510.35%-68.14%N/ALatest CELU, LONA, RNTX, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RNTXRein Therapeutics-$0.49-$0.19+$0.30-$0.19N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A4/30/2026Q4 2025CELUCelularityN/A-$0.85N/A-$0.85N/A$4.10 million3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/A3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06CELUCelularityN/A0.150.15LONAAthira PharmaN/A10.3810.38RNTXRein TherapeuticsN/A0.400.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ACELUCelularity19.02%LONAAthira Pharma57.12%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ACELUCelularity17.30%LONAAthira Pharma25.73%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/ACELUCelularity22028.95 million23.94 millionOptionableLONAAthira Pharma409.39 million6.98 millionN/ARNTXRein Therapeutics985.54 million81.18 millionN/ACELU, LONA, RNTX, and AARD HeadlinesRecent News About These CompaniesRein Therapeutics Expands Phase 2 RENEW Trial into United KingdomJune 11 at 8:00 AM | globenewswire.comRein Therapeutics Inc RNTXJune 7, 2026 | morningstar.comMRein Therapeutics (NASDAQ:RNTX) Upgraded by Wall Street Zen to "Hold" RatingJune 6, 2026 | americanbankingnews.comRein Therapeutics (NASDAQ:RNTX) Director Buys $16,747.50 in StockMay 29, 2026 | insidertrades.comRein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment OptionMay 18, 2026 | globenewswire.comInsider Buying: Rein Therapeutics (NASDAQ:RNTX) Insider Purchases 25,000 Shares of StockMay 14, 2026 | insidertrades.comRein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockApril 30, 2026 | globenewswire.comRein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary FibrosisApril 29, 2026 | globenewswire.comRein Therapeutics Stock Short Interest Report | NASDAQ:RNTX | BenzingaApril 14, 2026 | benzinga.comRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisMarch 3, 2026 | markets.businessinsider.comRein Therapeutics (RNTX) price target increased by 25.00% to 10.20February 4, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)January 23, 2026 | theglobeandmail.comRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisJanuary 20, 2026 | manilatimes.netMRein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Here’s WhyJanuary 9, 2026 | defenseworld.netDVoss Capital, Lp Buys 104,183 Shares of Rein Therapeutics (NASDAQ:RNTX) StockNovember 19, 2025 | insidertrades.comRein Therapeutics (RNTX) Price Target Decreased by 20.00% to 8.16November 17, 2025 | msn.comRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPFNovember 6, 2025 | finance.yahoo.comRein Therapeutics upgraded to Buy from Hold at BrooklineNovember 4, 2025 | msn.comWhy Is Rein Therapeutics Stock Trading Higher On Monday?November 3, 2025 | benzinga.comRein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisNovember 3, 2025 | taiwannews.com.twTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, LONA, RNTX, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$3.90 +0.26 (+7.14%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.89 -0.01 (-0.26%) As of 06/12/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Celularity NASDAQ:CELU$0.71 -0.01 (-1.91%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.73 +0.02 (+2.68%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Athira Pharma NASDAQ:LONA$8.35 -0.14 (-1.65%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$8.44 +0.09 (+1.02%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Rein Therapeutics NASDAQ:RNTX$0.96 +0.03 (+3.49%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.43%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
